Mesh Bio

Singapore-founded health technology startup Mesh Bio has announced the regulatory approval of its HealthVector® Diabetes as a Software Medical Device (SaMD) by the Health Sciences Authority (HSA). HealthVector® Diabetes will be involved in an implementation pilot at Singapore General Hospital (SGH), Tan Tock Seng Hospital (TTSH), and selected polyclinics…

Mesh Bio, a Singapore-based health deep tech startup, announced Thursday that it had raised an undisclosed amount of funding from East Ventures, a venture capital firm focusing on Southeast Asia. The funding will be allocated to further develop the digital twin technologies in chronic disease management and to expand its services across Southeast Asia,…